Smithfield Trust’s Cytokinetics CYTK Stock Holding History

Smithfield Trust’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13K	Hold	155	–	–	﹤0.01%	861
2026 Q1	$10K	Hold	155	–	–	﹤0.01%	883
2025 Q4	$10K	Hold	155	–	–	﹤0.01%	876
2025 Q3	$9K	Hold	155	–	–	﹤0.01%	873
2025 Q2	$5K	Hold	155	–	–	﹤0.01%	962
2025 Q1	$6K	Hold	155	–	–	﹤0.01%	939
2024 Q4	$7K	Hold	155	–	–	﹤0.01%	926
2024 Q3	$8K	Hold	155	–	–	﹤0.01%	872
2024 Q2	$8K	Hold	155	–	–	﹤0.01%	851
2024 Q1	$11K	Hold	155	–	–	﹤0.01%	819
2023 Q4	$13K	Hold	155	–	–	﹤0.01%	783
2023 Q3	$5K	Hold	155	–	–	﹤0.01%	900
2023 Q2	$5K	Hold	155	–	–	﹤0.01%	919
2023 Q1	$5K	Hold	155	–	–	﹤0.01%	887
2022 Q4	$7K	Hold	155	–	–	﹤0.01%	832
2022 Q3	$8K	Hold	155	–	–	﹤0.01%	808
2022 Q2	$6K	Hold	155	–	–	﹤0.01%	919
2022 Q1	$6K	Hold	155	–	–	﹤0.01%	939
2021 Q4	$7K	Hold	155	–	–	﹤0.01%	918
2021 Q3	$6K	Hold	155	–	–	﹤0.01%	963
2021 Q2	$3K	Hold	155	–	–	﹤0.01%	1027
2021 Q1	$4K	Hold	155	–	–	﹤0.01%	1019
2020 Q4	$3K	Hold	155	–	–	﹤0.01%	1028
2020 Q3	$3K	Buy	+155	New	+$3.63K	﹤0.01%	999

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smithfield Trust's CYTK Position: Q2 2026 in Review

Smithfield Trust held its Cytokinetics (CYTK) position steady in Q2 2026 at 155 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #861.

Smithfield Trust first reported a position in CYTK in Q3 2020 and has held it in 24 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Smithfield Trust held 155 shares of Cytokinetics worth $13K as of Q2 2026.
Smithfield Trust left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up ﹤0.01% of Smithfield Trust's portfolio in Q2 2026, its #861 holding.
Smithfield Trust first reported a position in Cytokinetics in Q3 2020 and has held it in 24 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Smithfield Trust's 13F filing for Q2 2026, filed 5 Aug 2026.